Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential
On Tuesday, D Boral Capital initiated coverage on Tevogen Bio Holdings Inc. TVGN, a clinical-stage immunotherapy company.
Tevogen Bio Holdings Inc.: Excessive Insider Ownership And Poised For A Seasonal Rebound
Initiated a small position in Tevogen Bio Holdings Inc. due to a promising pipeline and favorable seasonal patterns, despite only one Wall Street analyst covering it. Tevogen Bio develops T-cell therapies for infectious diseases, cancers, and neurological disorders, with TVGN 489 completing Phase 1 trials for Long COVID and COVID-19. The stock has experienced significant price fluctuations, with lows likely due to tax loss selling and potential upside from the Santa Claus Rally and January effect.
Why Is Small-Cap Tevogen Bio Stock Rocketing Higher On Thursday?
On Thursday, Tevogen Bio Holdings Inc. TVGN announced its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion.
